|
|
| Antalgiques > Etude de marché sectorielle |
| US State Market Index: Antacids |
|
|
|
|
€ 475,00 |
Editeur
: |
BizMiner |
Langue
: |
Anglais |
Date de publication : |
Juillet 2006 |
Taille du document : |
12 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Analgesics
651 pages | Janvier 2006 |
This report analyzes the worldwide markets for Analgesics in Millions of US$.
The major product segments analyzed are Internal Analgesics, and External Analgesics.
The sub-product segments discu |
2 699,00 €
|
| |
| |
US State Market Index: Anesthetics, in bulk form
12 pages | Juillet 2006 |
The metrics in this report cover three year trends in Anesthetics, in bulk form [Manufacturing sector], broken out on a state-by-state basis.
Analysis is based on data applied from 11 industry firm |
475,00 €
|
| |
| |
Pain Therapeutics 2005: Market Dynamics and Outlook
249 pages | Mai 2005 |
Pain Therapeutics 2005: Market Dynamics and Outlook provides detailed analysis and information concerning the global market for pain therapeutics, R&D pipelines and company involvement in this field.A |
1 599,20 €
|
| |
| |
Disease and Therapy Review: Migraine
9 pages | Février 2007 |
The Migraine Disease and Therapy Review provides prevalence numbers and percentages for major countries worldwide.
Diagnosis of migraine is covered, along with information on treatment options for |
720,00 €
|
| |
| |
US External Analgesics 2005
12 pages | Juin 2005 |
Snapdata's US External Analgesics 2005 report provides 2004 year-end market data, with 2005 estimates and five-year forecasts.
The report gives an instant overview of the US external analgesic mark |
240,00 €
|
| |
| |
Drug Safety in the Post-Vioxx Era: New legislation, regulation and company strategies in Europe and the US
175 pages | Juillet 2005 |
The new report, Drug Safety in the Post-Vioxx Era: New legislation, regulation and company strategies in Europe and the US, examines the actions taken by legislative and regulatory bodies in response |
1 520,00 €
|
| |
| |
UK Analgesics 2007
12 pages | Avril 2007 |
Snapdata's Snapshots UK Analgesics 2007 provides 2005 year-end market size data, with 2006 estimates, 4 years of historical data and five-year forecasts.
The Snapshots report gives an instant overv |
240,00 €
|
| |
| |
Anesthesia Competitors
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
Worldwide Anti-Inflammatory Therapeutic Market Share by Disease Category, 2005 and 2010
1 pages | Octobre 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
Event Analysis and Response Service: Cox-2s - Cox-2 Crisis Dents Big Pharma Confidence
95 pages | Juin 2005 |
IntroductionOn 30th September 2004, Merck withdrew its blockbuster drug Vioxx from the global market after trial data reinforced the suspicion that it increased the risk of cardiovascular events.
V |
9 120,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| US State Market Index: Antacids |
|
|
The metrics in this report cover three year trends in Antacids [Manufacturing sector], broken out on a state-by-state basis. Analysis is based on data applied from 1 industry firms. Industry market vitality measures for each state are benchmarked against US averages for the industry, creating easy comparison of state-by-state performance. Industry sales are detailed for both company-wide headquarters data and locally generated sales levels. The report also compares proprietary measures in each state and the US, including failure rates, entrepreneurial activity and new branch development rates in the industry.
|
|
State Market Index Contents
P1-3 Introduction and context for the measures
P4:Industry population and segmentation
P5:Establishment,company and branch failure rates
P6:Total industry sales volume (reported and locally generated)
P7:Average annual reported sales
P8:Average annual generated sales
P9:Startup activity, new branch development,employment concentration
P10:Overall Index
P11:About the data
|
|
|
PPLSEN
|
|
|
|
|
